|
Late Breaker Abstract Submission
The deadline for late breaker abstract submission is November 16, 2009. All submissions should not exceed 450 words.
The Scientific Committee requests that authors submit their abstracts electronically via the Conference website. To submit electronically please click on the button at the bottom of the page and follow the step-by-step directions, which will enable you to upload the file containing your abstract from the computer system that you are using to access this website. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.
Abstract Guidelines
Format
The body of the uploaded abstract submission should not exceed 450 words; this limit excludes the title, authors and affiliations.
Clearly define all concepts and abbreviations at first use. If English is not your primary language, attempt to have your abstract reviewed by a native English speaker. To be acceptable, abstracts shall contain a concise statement of the research. It is recommended that the author follow the structured format below:
Title (not included in 450 word limit)
Use a short and concise title that indicates the content of the abstract. Capitalize the first letter of each word except prepositions, articles, and species names. Species names should be spelled out at first use. Italicize scientific names of organisms (example: Staphylococcus aureus). For therapeutic agents, only generic names may be used (no trade names are permitted in abstract titles).
Authors/Affiliations (not included in 450 word limit)
Authors' names should be entered using initial(s) for the first and middle names followed by the full last name, with presenting author underlined (e.g. AN Author1, AN Author2 and AN Author3).
All author affiliations should be entered as follows:
1 University of London, London, UK; 2 University of Frankfurt, Frankfurt, Germany; and 3 University of Paris, Paris, France.
Background
State the problem under investigation or a hypothesis. For therapeutic agents, only generic names may be used (no trade names are permitted). No figures or tables are allowed.
Methods
Explain the experimental methods used. For therapeutic agents, only generic names may be used (no trade names are permitted). No figures or tables are allowed.
Results
List the essential results obtained in summary form, with enough quantitative data to permit evaluation by reviewers. For therapeutic agents, only generic names may be used (no trade names are permitted). No figures or tables are allowed.
Conclusion
Summarize the findings. It is unacceptable to use statements such as "the results will be discussed". For therapeutic agents, only generic names may be used (no trade names are permitted). Simple figures or tables are allowed. Note that figures or tables may be resized or reformatted if necessary.
Additional Abstract Information
In addition to the uploaded abstract, the following additional information will be collected on the abstract submission form:
Contact Information
The presenting author must enter a complete address to ensure that correspondence arrives promptly and easily.
Preferred Form of Presentation
Poster, Oral, Either
- back to top -
Abstract Category
For purposes of review and programming, abstracts are divided into topical categories. Selection of the most appropriate category is important as it determines who reviews your abstract. The Organizing Committee reserves the right to reassign your abstract to a more appropriate category.
- Advances in HCV and HBV Cell-based Assays & Animal Models
- Clinical Development of HBV/HCV Inhibitors
- Co-infection with HIV and Other Viruses
- Hepatocellular Carcinoma and Fibrosis
- Immunology & Vaccine Development
- Next Generation of HBV and HCV Inhibitors
- New Therapeutic Approaches, Combinations, Pharmacology, and Emerging Targets
- Optimizing Outcome of Therapeutics for HBV/HCV
- Pathogenesis, Therapeutics, Viral Dynamics and Emerging Viruses
- Resistance to Antiviral Agents, Replication Fitness and Vaccine Escape Mutants
- Diagnostic Approaches and Non-invasive Markers
Abstract Title (should be the same as in the uploaded abstract)
Use a short and concise title that indicates the content of the abstract. Capitalize the first letter of each word except prepositions, articles, and species names. Species names should be spelled out at first use. Italicize scientific names of organisms (example: Staphylococcus aureus). For therapeutic agents, only generic names may be used (no trade names are permitted in abstract titles).
Sample Abstract
To view a sample abstract, click here.
The sample form is an Adobe Acrobat document. If your computer cannot read the sample, please click here to download Adobe's free Acrobat Reader.
- back to top -
Abstract Notifications
Notifications of acceptance and format of presentation (oral or poster presentation) will be announced on November 23, 2009. It is the responsibility of the corresponding/presenting author to inform all co-authors of the disposition status. If you have not received notification by November 25, 2009, please call +1 770 573 2627.
If an abstract is accepted, one author is required to register for the conference and present the paper as scheduled. Guidelines for preparing your poster presentations will be sent if your abstract is accepted.
- back to top -
- back to top -
|
